Form 4: Privia Health Exec Sells Shares Under 10b5-1 Plan

David Mountcastle, EVP & Chief Financial Officer of Privia Health Group, Inc., reported transactions involving the sale of common stock and the exercise of stock options under a pre-arranged Rule 10b5-1 trading plan.

Summary

• David Mountcastle, EVP & Chief Financial Officer of Privia Health Group, Inc., executed a Rule 10b5-1 trading plan on June 26, 2026.
• Under this plan, 17,196 shares of common stock were acquired and subsequently sold.
• The sale of these shares occurred at a weighted average price, with individual transactions ranging from $25.00 to $25.68 per share, totaling an aggregate sale price that can be inferred from the reported weighted average price and number of shares.
• Additionally, Mountcastle exercised several stock options, acquiring a total of 12,194 shares (5,962 + 1,001 + 1,336 + 8,897).
• Following these transactions, Mountcastle beneficially owns 211,462 shares directly and an additional 8,695 shares indirectly through his spouse.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral to slightly negative due to the significant sale of shares by a key executive, despite the use of a Rule 10b5-1 plan which mitigates insider trading concerns.

Positives

• The transactions were conducted under a Rule 10b5-1 trading plan, indicating adherence to pre-determined trading strategies designed to avoid insider trading concerns.
• All stock options exercised were fully vested.
• The reporting person has committed to providing detailed information on individual sale prices upon request, demonstrating transparency.

Negatives

• A significant number of shares (17,196) were sold by a key executive.
• The sale of shares at prices up to $25.68 suggests a potential peak in the stock price around the transaction date.

Risks

• The sale of a substantial number of shares by a high-ranking executive could be interpreted negatively by the market, potentially impacting investor sentiment.
• The weighted average sale price indicates a range of prices, and the higher end of this range might represent a missed opportunity for further gains if the stock price continues to rise.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing, as it solely reports on past transactions.

Industry Context

StockSavvy.ai notes that Form 4 filings, particularly those involving significant share sales by executives under Rule 10b5-1 plans, are common in the healthcare services sector. These plans are designed to provide liquidity for executives while adhering to insider trading regulations. The reported sale price range provides a benchmark for recent trading activity.

Stakeholder Impact

• Shareholders may view the executive's sale of shares with caution, potentially leading to short-term downward pressure on the stock price.
• Employees with stock options may be influenced by the executive's exercise and sale strategy.
• Creditors and suppliers are unlikely to be directly impacted by this specific insider transaction.

Next Steps

• The reporting person may continue to execute trades under the existing Rule 10b5-1 plan.
• Further transactions by this reporting person or other insiders may be reported in subsequent filings.

Key Dates

Recommendation

The filing reports a significant sale of shares by a key executive under a pre-arranged plan. While the Rule 10b5-1 plan suggests a structured approach to selling, the volume of shares sold warrants a cautious 'hold' recommendation. Investors should monitor future filings and company performance for further direction.

Keywords

Privia Health, PRVA, Form 4, Insider Trading, Rule 10b5-1, Stock Options, Share Sale, Executive Transactions, Beneficial Ownership, SEC Filing